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Abstract 
Potential Mechanisms For Amelioration of Type 2 Diabetes Following Bariatric Surgery 
By: Melissa Anne Reed 
July, 2011 
Directors:  G. Lynis Dohm and Timothy P. Gavin 
Major Department:  Department of Kinesiology 
 Severe obesity and Type 2 Diabetes (T2DM) are worldwide health concerns 
reaching epidemic proportions.  Roux-en-Y gastric bypass (RYGB) has been shown to 
elicit a rapid and durable improvement and/or remission of T2DM in as little as one 
week following surgery in approximately 80% of patients, however the exact 
mechanism(s) responsible for this remission remain unknown.  It was the central 
hypothesis of this project that T2DM is rapidly ameliorated following RYGB in part by 
increasing skeletal muscle insulin sensitivity   
 Study One:  To test this hypothesis we examined insulin sensitivity and insulin 
secretion in severely obese non-diabetic and T2DM women prior to RYGB and 1 week 
and 3 months post-RYGB using an insulin-modified intravenous glucose tolerance test 
(IVGTT) with Minimal Model analysis.  Insulin sensitivity and insulin secretion were 
measured in lean women as a control group.  One week after RYGB, insulin sensitivity 
in T2DM doubled compared to pre-RYGB but was still impaired (SI approximately 50% 
of lean controls) and insulin secretion was improved but not restored (AIRg 
approximately 50% of lean controls).  Remarkably, fasting insulin decreased one week 
post-RYGB and was no different from lean controls in both the T2DM and non-diabetic 
groups in spite of continued elevated glucose in the T2DM patients compared to lean, 
  
suggesting that there is no longer a relationship between fasting insulin and glucose 
following RYGB.   
 The main finding in this study was that RYGB reverses hyperinsulinemia, which 
is beneficial for a multitude of reasons.  Hyperinsulinemia is a central factor in the 
cluster of disorders of the metabolic syndrome and is associated with increases in 
cardiovascular disease and overall all-cause mortality.  Consistent with previous 
reports, approximately 25% of patients in Study One did not experience an 
improvement in their T2DM post-RYGB.  The rapid reversal of hyperinsulinemia 
following RYGB and 25% non-resolution of T2DM led to two further questions: 1) Is it 
possible, pre-RYGB, to predict T2DM resolution following RYGB? and 2) Can 
hyperinsulinemia induce skeletal muscle insulin resistance?  
 Study Two:  To follow-up question number one we examined the T2DM cohort 
from Study One to determine the remission of T2DM following RYGB.  Three patients 
exhibited complete T2DM remission 3 months post-RYGB (defined as fasting plasma 
glucose (FPG) < 100mg/dL), three experienced improvement but FPG remained 
impaired (FPG of 100-125 mg/dL) and two patients did not experience improvement in 
their T2DM (FPG > 125 mg/dL).  We found that pre-RYGB insulin sensitivity and 
duration of diabetes were significantly correlated with FPG at 3 months post-RYGB 
suggesting that preserving insulin sensitivity may be essential in the remission of T2DM 
following RYGB.   
 Study Three:  To investigate the effects of hyperinsulinemia on skeletal muscle, 
primary skeletal myotubes from lean (LN) (23.0 + 1.7 kg/m2) insulin sensitive (HOMA-IR: 
1.3 + 0.3) and severely obese (OB) (41.4 + 3.8 kg/m2) insulin resistant (HOMA-IR: 5.8 + 
  
1.1) individuals were exposed to physiological levels of hyperinsulinemia for 4 days.  It 
was hypothesized that exposure to chronic hyperinsulinemia (5000 pM) would down-
regulate insulin signaling.  Following the 4-day incubation, cells were exposed to a 15 
minute acute supraphysiological (100nM) insulin stimulation to determine insulin-
stimulated insulin signaling.  As insulin resistance is associated with mitochondrial 
dysfunction we also hypothesized that chronic hyperinsulinemia would decrease 
mitochondrial content and subsequently decrease fatty acid oxidation.   
 Following the 4-day hyperinsulinemic incubation insulin signaling was not down-
regulated in either group as measured by Akt and AS160 phosphorylation.  Rather, 
AS160 phosphorylation was increased in the LN, but not OB following chronic 
hyperinsulinema.  Complete oxidation of fatty acids was significantly reduced and 
incomplete oxidation was significantly higher in OB compared to LN independent of 
insulin incubation.  Mitochondrial content in myotubes was not different between the 
groups.  These data suggest that lean insulin sensitive myocytes respond to chronic 
hyperinsulinemia by increasing AS160 phosphorylation.  This response is not observed 
in cells from obese indicating that perhaps insulin sensitive myocytes exhibit a flexibility 
in response to hyperinsulinemia that is not present in insulin resistant myotubes 
suggesting that hyperinsulinemia-induced insulin resistance may not act through Akt 
and AS160.      Together, these studies suggest that RYGB reverses hyperinsulinemia in as little 
as one-week following surgery, in spite of continued insulin resistance, indicating the 
regulation of insulin by fasting glucose is altered following RYGB.  Clinically, preserving 
insulin sensitivity prior to RYGB appears to be important, as patients that exhibit greater 
  
insulin sensitivity prior to RYGB experience lower FPG post-RYGB.  Additionally, cells 
from lean, insulin sensitive individuals were capable of responding to physiological 
hyperinsulinemia by increasing insulin signaling in response to an acute insulin stimulus 
whereas the cells from obese, insulin resistant individuals demonstrate an inability to 
respond to hyperinsulinemia. 
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CHAPTER 1: Introduction 
Prevalence, pathophysiology and treatment of T2DM 
 The prevalence of obesity and T2DM is increasing rapidly, reaching epidemic 
proportions. This is due to many factors including an overall increasing sedentary 
lifestyle, caloric overconsumption, and an extended lifespan. It is estimated that in the 
year 2000 approximately 150 million people worldwide suffered from T2DM and that 
number is expected to increase to 221 million individuals by 2010, indicating a nearly 
45% increase (Zimmet, Alberti, & Shaw, 2001). It is clear that both obesity and T2DM 
are two of the greatest public health concerns in the upcoming decades. 
 T2DM is characterized by glucose intolerance (DeFronzo, 2004), insulin 
resistance, pancreatic dysfunction and a state of chronic inflammation (Wellen & 
Hotamisligil, 2005). T2DM is a multi organ and system disorder and is the most 
common cause of renal disease, blindness and limb amputations. In addition, the 
diagnosis of T2DM significantly increases the risk for cardiovascular disease and 
coronary artery disease. T2DM is responsible for significant health care costs as well. 
An estimated $153 billion annually are spent treating T2DM and related complications 
(International Diabetes Federation, 2007).  
 There are a number of treatment options available for T2DM such as lifestyle 
modifications involving changing dietary patterns and increasing physical activity as it 
has been shown that decreasing caloric intake and increasing regular exercise induces 
an increase in insulin sensitivity (Dixon et al., 2008). If these conventional mechanisms 
are unable to maintain euglycemia, pharmaceutical therapy and eventually insulin may 
be necessary to add to the treatment regimen to restore glucose homeostasis. Common 
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pharmaceuticals employed to treat T2DM and in turn increase insulin sensitivity are 
thiazolidinedione’s (TZD’s) that act on increasing the activity of peroxisome-proliferating 
activator receptor gamma (PPARγ) (Jay & Ren, 2007) (Towler & Hardie, 2007) and 
metformin which activates AMP-associated protein kinase (AMPK) and stimulates fatty 
acid transport into the mitochondria for subsequent oxidation (Ferre, Azzout-Marniche, 
& Foufelle, 2003; McGarry, 2002).  
 Metformin also increases insulin sensitivity by reducing hepatic glucose output 
and increasing peripheral skeletal muscle glucose uptake (Hundal & Inzucchi, 2003). 
Additionally, recent research suggests that metformin may act in reducing whole body 
inflammation as measured by C-Reactive protein (CRP), vascular cell adhesion 
molecule -1 (VCAM–1) and macrophage migration inhibitory factor (Dandona et al., 
2004; Morin-Papunen et al., 2003). This makes metformin an attractive therapy for 
obese T2DM patients as they commonly experience impaired insulin signaling and 
decreased fatty acid oxidation.  
Surgical Treatment for T2DM.  
 Roux-en-Y gastric bypass (RYGB) appears to be the most successful treatment 
for T2DM as it has been proven to provide rapid and durable resolution of T2DM (Pories 
et al., 1995).  RYGB, developed for the treatment of morbid obesity, involves gastric 
restriction, bypassing of the proximal small intestine and rerouting of nutrients to the 
distal small intestine (Figure 1).  One of the surprising benefits of RYGB, shown as early 
as 1984, is the durable remission of T2DM (Flickinger et al., 1984). The exact 
mechanisms of this reversal remain largely unknown. The main theories of T2DM 
reversal following RYGB are substantial weight loss, caloric restriction and/or bypassing 
   3 
of the proximal small intestine. Studies have shown that T2DM is resolved in patients as 
early as days after surgery when significant weight loss has not occurred (Pories et al., 
1995). In addition, it has been documented that 
caloric restriction does not result in similar 
improvements in glucose homeostasis as RYGB 
when comparing patients one-month post RYGB 
with a cohort that experienced calorically induced, 
but similar weight loss (Laferrere et al., 2008). This 
supports the hypothesis that weight loss alone may 
not be responsible for the reversal of T2DM and that 
bypass of the proximal small intestine during RYGB 
may contribute to the reversal of T2DM.  
 
Insulin sensitivity and bariatric surgery.  
 Skeletal muscle is responsible for approximately 70-80% of glucose disposal and 
is also the primary site for peripheral insulin resistance (Shulman et al., 1990). A 
reduction in skeletal muscle insulin sensitivity and an increase in insulin resistance are 
hallmark defects that occurs in T2DM (Corcoran, Lamon-Fava, & Fielding, 2007). 
Similarly, a reduction in skeletal muscle insulin sensitivity appears to be a leading factor 
in the development of T2DM (Petersen & Shulman, 2006). 
 Skeletal muscle insulin signaling begins with the binding of insulin and 
subsequent autophosphorylation of the insulin receptor (IR) and cascade of events that 
culminates with the translocation of glucose transporter 4 (GLUT4), which is responsible 
Figure 1. Roux-en-Y gastric bypass (RYGBP) 
includes the creation of a small gastric pouch while 
the jejunum is divided 30–50 cm distal to the 
ligament of Treitz. The distal limb of the jejunum is 
then anastomosed to the small gastric pouch and a 
jejuno–jejunostomy is performed 50 to 150 cm 
distal from the gastrojejunostomy. Adapted from 
Rubino and Marescaux 2004. 
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for glucose transport into skeletal muscle cells (Figure 2). Once the insulin receptor is 
activated, tyrosine residues on insulin receptor substrate (IRS) are phosphorylated and 
phosphoinositide-3-kinase (PI3K) is activated which then stimulates phosphoinositide 
dependent kinase 1 (PDK1). 
PDK1 subsequently activates 
atypical protein kinase C 
(aPKC) and Akt (protein kinase 
B). Activation of aPKC then 
promotes both translocation of 
GLUT4 to the cell membrane 
and akt phosphorylation. Akt 
phosphorylation activates akt 
substrate 160 (AS160), which also promotes GLUT4 translocation.     
 Insulin stimulated glucose transport is decreased in patients with T2DM (Dohm et 
al., 1988). There are numerous studies that confirm both decreased tyrosine kinase 
activity on the insulin receptor in obese and T2DM skeletal muscle (Caro et al., 1987; 
Itani, Zhou, Pories, MacDonald, & Dohm, 2000) and increased serine phosphorylation 
of IRS-1-Ser312 which interferes with and down-regulates the insulin signaling cascade 
(Dohm et al., 1988; Zhou, Dolan, & Dohm, 1999).  
 T2DM is rapidly reversed following bariatric surgery (Pories et al., 1995) and 
skeletal muscle insulin sensitivity increases significantly as well (Friedman et al., 1992). 
More recently, there have been conflicting reports on the recovery of insulin sensitivity 
following RYGB with studies finding increases within weeks following surgery 
Figure 2. Insulin signaling cascade, involvement of NEFA’s, DAG’s and Fatty acyl‐CoA’s and subsequent activation of PKC’s  (adapted from Dohm) 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(Wickremesekera, Miller, Naotunne, Knowles, & Stubbs, 2005) and others not finding 
improvements in insulin sensitivity until significant weight loss occurs (Campos et al., 
2010). The homeostasis model assessment of insulin resistance (HOMA), which is a 
surrogate indicator of insulin sensitivity, primarily hepatic insulin sensitivity because it is 
calculated from fasting glucose and insulin values improves dramatically within the first 
month following RYGB indicating that insulin resistance is improved long before 
significant weight changes (Ferrannini & Mingrone, 2009; Wickremesekera et al., 2005).  
 It is possible that there are two or more distinct mechanisms that contribute to the 
reversal of T2DM following RYGB. Many studies have reported improvements in HOMA 
following RYGB (Ferrannini & Mingrone, 2009; Lima et al.; Wickremesekera et al., 
2005) and this is likely due to decreased hepatic glucose output and decreased fasting 
insulin levels following RYGB (Bikman et al., 2008; Friedman et al., 1992).   
Insulin Secretion and bariatric surgery 
 As T2DM progresses there is a decrease of β-cell sensitivity to glucose which 
appears to be independent of insulin resistance (Ferrannini et al., 2005).  While the 
restoration of insulin sensitivity following bariatric surgery is widely accepted, less is 
known regarding the response of insulin secretion to bariatric surgery.  Though severe 
obesity is associated with insulin resistance, it appears that β cell function may be 
preserved (Camastra et al., 2005).  Long term results from studies indicate that first 
phase insulin secretion (in response to an IVGTT) one year post-surgery is improved 
(Polyzogopoulou, Kalfarentzos, Vagenakis, & Alexandrides, 2003) and that by two years 
post-surgery, β cell glucose sensitivity recovers (Camastra et al., 2005).  There is little 
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data available regarding the response of insulin secretion shortly following bariatric 
surgery.   
 One mechanism by which insulin secretion is proposed to improve following 
bariatric surgery is through increases in glucagon-like peptide 1 (GLP1) post-surgery.  
GLP-1 is an incretin hormone secreted by L cells throughout the gut although 
predominantly in the distal small bowel, in response to nutrient delivery (Theodorakis et 
al., 2006).  GLP-1 accounts for approximately 50% of nutrient stimulated insulin 
production (Preitner et al., 2004) and it acts to both increase β cells mass (Stoffers et 
al., 2000) and prevent β cell apoptosis (Li et al., 2003).  GLP-1 response is impaired in 
both obesity and T2DM (Muscelli et al., 2008) but improves dramatically in T2DM 
patients following bariatric surgery (Laferrere et al., 2008).  Potential mechanisms for 
the post-surgery increase in GLP-1 include the exclusion of nutrients from the foregut, 
often termed the “foregut hypothesis” (Rubino & Marescaux, 2004) or a rapid delivery of 
nutrients to the L cells in the distal small bowel, referred to as the “hindgut” hypothesis 
(Strader et al., 2005).        
Lipid accumulation and duration of diabetes in skeletal muscle insulin resistance. 
 A potential mechanism contributing to skeletal muscle insulin resistance in obese 
and T2DM individuals is an increase in fatty acids and fatty acid intermediates. Studies 
have confirmed that skeletal muscles from obese individuals display a high 
concentration of intramyocellular lipid accumulation (IMCL) (Malenfant et al., 2001) yet 
still tend to utilize glucose as the preferred substrate for ATP production (Kelley, 
Goodpaster, Wing, & Simoneau, 1999). The accumulation of skeletal muscle lipids is 
closely associated with defects in skeletal muscle insulin signaling (McGarry, 2002).  
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Insulin resistance in skeletal muscle is associated with both reduced lipid oxidation and 
also increased lipid accumulation in patients with T2DM (Kelley & Simoneau, 1994).  
Additionally, lipid accumulation in skeletal muscle and insulin resistance are inversely 
correlated (Pan et al., 1997).  It has been shown that reduced lipid oxidation in the 
skeletal muscle of T2DM patients is carried over into cell culture such that reduced 
skeletal muscle lipid oxidation present in diabetics in vivo is retained in human skeletal 
muscle myotubes from T2DM patients (Gaster, Rustan, Aas, & Beck-Nielsen, 2004).  
This indicates that skeletal muscle myotubes from T2DM patients may have inherited 
defects in fatty acid metabolism. 
 Studies have also shown that there are defects in fatty acid metabolism 
(Simoneau & Kelley, 1997) and decreased mitochondrial fatty acid oxidation (He, 
Watkins, & Kelley, 2001) in skeletal muscle of insulin resistant and T2DM individuals.  
Increased lipid accumulation and reduced fatty acid oxidation may result in increased 
fatty acid availability in the skeletal muscle of T2DM patients.  One of the consequences 
of increased fatty acid availability is the increase in intracellular intermediates such as 
LCFA-CoA’s, DAG’s and ceramides which can potentially result in increased skeletal 
muscle insulin resistance and decreased glucose metabolism (Kraegen & Cooney, 
2008).   
Skeletal Muscle Mitochondria and Insulin Resistance 
 The role of mitochondria in insulin resistance is quite controversial.  Skeletal 
muscle mitochondria are the site for fatty acid oxidation.  Decreased fatty acid oxidation 
coupled with increased glycolytic activity have been linked to insulin resistance 
(Simoneau & Kelley, 1997) in obese individuals.  Also, decreased mitochondrial volume 
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has been associated with insulin resistance as well (Kelley, He, Menshikova, & Ritov, 
2002).  The skeletal muscle of obese individuals has been shown to exhibit decreased 
oxidative enzyme capacity and smaller mitochondria in addition to reduced electron 
transport when compared with their lean counterparts (Kelley et al., 2002; Simoneau, 
Veerkamp, Turcotte, & Kelley, 1999).  However, it remains unclear if these differences 
between lean and obese are due to mitochondrial dysfunction, a decrease in 
mitochondrial content, or both, in obese compared to lean individuals. 
 Additionally, there are studies that have shown situations where mitochondrial 
function and content are not related to insulin sensitivity, particularly with regards to 
T2DM individuals.  Recently, a large clinical trial demonstrated that mitochondrial 
capacity is not related to insulin action in T2DM (Bajpeyi et al., 2011) and other work 
has shown that in rats, the implementation of a high fat diet induced insulin resistance 
but also increased mitochondria in skeletal muscle (Hancock et al., 2008).  Further, a 
report concluded that animals that suffer from mitochondrial dysfunction and reduced 
oxidative phosphorylation do not exhibit insulin resistance (Pospisilik et al., 2007).  
RYGB and T2DM Remission 
 Little is known regarding defects that may occur in insulin signaling pathways and 
substrate metabolism as diabetes progresses.  As T2DM progresses it gets increasingly 
more difficult to treat and this appears to be consistent in surgical situations as well 
(Buchwald et al., 2004; Buchwald et al., 2009; Schauer et al., 2003).  We have found 
following RYGB that there are some patients that do not experience diabetes resolution, 
which is consistent with other reports that approximately 15-25% of T2DM RYGB 
patients do not have diabetes resolution (Buchwald et al., 2004; Buchwald et al., 2009). 
   9 
 One of the main factors in this lack of remission appears to be duration of 
diabetes (Renard, 2009). Schauer, et. al (2003) found that 95% of patients who had 
T2DM for less than 5 years experienced complete reversal following RYGB while only 
54% of those patients that had the disease for greater than 10 years experienced 
complete reversal of diabetes (Schauer et al., 2003).  This is agreement with other 
studies where the duration of diabetes was inversely correlated with diabetes resolution 
(Smith, Hinojosa, Reavis, & Nguyen, 2008). 
Central Hypothesis 
It is the main hypothesis of this proposal that bypass of the proximal small 
intestine significantly contributes to rapid T2DM resolution in response to 
RYGB in part through increases in skeletal muscle insulin sensitivity. We will 
also investigate if there are any pre-RYGB factors that can predict post-RYGB 
remission and lastly if chronic hyperinsulinemia decreases insulin signaling, 
mitochondrial content and fatty acid oxidation in lean insulin sensitive 
individuals and obese insulin resistant individuals.  In order to examine these 
hypotheses we have developed the following Specific Aims. Specific Aim 1: To 
investigate the role of proximal small intestine bypass and weight loss in insulin 
sensitivity improvements following gastric bypass surgery in T2DM. It has been 
documented that RYGB performed in morbidly obese patients results in a reversal in 
T2DM in approximately 75-85% of cases. This reversal occurs before significant 
weight loss suggesting that proximal small intestine bypass may contribute to this 
reversal.  In humans, we investigated the effects of proximal small intestine bypass 
and weight loss following gastric bypass surgery on insulin sensitivity by the 
  10 
following: 1) Determining if insulin sensitivity is improved 1 week following gastric 
bypass when weight loss is minimal and 2) Determining if insulin sensitivity is 
improved to a greater extent 3 months following gastric bypass when weight loss is 
significant.  As a follow-up to this study, specific aim 2 was developed which was To 
determine if pre-RYGB insulin sensitivity and/or insulin secretion is associated with 
post-RYGB T2DM remission.  Little is known regarding the approximately 20% of 
type 2 diabetic patients that do not experience T2DM improvement following RYGB.  
Some factors that consistently appear to affect T2DM remission following RYGB 
include duration and severity of the disease.  In addition, reports have indicated that 
glycosylated hemoglobin (HbA1c), fasting plasma glucose and body mass index 
(BMI) may also contribute to outcomes of T2DM remissions following RYGB.  We 
investigated the effects of pre-RYGB insulin sensitivity and insulin secretion on post-
RYGB T2DM remission in an attempt to determine if either insulin sensitivity and/or 
insulin secretion can predict post-RYGB T2DM remission.  Lastly, in specific aim 3 
we investigated if chronic hyperinsulinemia decreases skeletal muscle insulin 
signaling, mitochondrial content and fatty acid oxidation in cells from lean insulin 
sensitive and obese insulin resistant individuals.  It has been observed that long-term 
diabetics have a greater resistance to diabetes resolution following bariatric surgery 
as opposed to shorter duration diabetics, potentially due to chronic exposure to 
hyperinsulinemia.  Our pilot data suggested that decreased skeletal muscle insulin 
sensitivity in long duration diabetics is associated with poor T2DM resolution. We 
investigated if skeletal muscle from lean insulin sensitive and obese insulin resistant 
individuals exposed to chronic hyperinsulinemia exhibit decreases in insulin signaling, 
  11 
mitochondrial content and fatty acid oxidation.  In doing this we assessed if: 1) 
skeletal muscle insulin signaling is decreased following chronic hyperinsulinemia in 
lean insulin sensitive and obese insulin resistant individuals and 2) if skeletal muscle 
mitochondrial content and fatty acid oxidation is decreased following chronic 
hyperinsulinemia in lean insulin sensitive and obese insulin resistant individuals.   
 
 
 
 
 
 
 CHAPTER 2: Roux-en-Y Gastric Bypass Corrects Hyperinsulinemia 
  Implications for the Remission of Type 2 Diabetes  
Melissa A. Reed1, Walter J. Pories2, William Chapman2, John Pender2, Rita Bowden2, 
Hisham Barakat3, Timothy P. Gavin1, Tom Green3, Ed Tapscott4, Donghai Zheng1, 4, 
Nigel Shankley5, Lynn Yieh5, David Polidori5, Steven P. Piccoli6, Leona Brenner-Gati7, 
and G. Lynis Dohm4 
1Departments of Exercise and Sport Science, 2Surgery, 3Internal Medicine and 
4Physiology, East Carolina University, Greenville NC  
5Johnson and Johnson Pharmaceutical Research & Development, L.L.C., San Diego, 
CA  
6Johnson and Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ  
7Johnson and Johnson Pharmaceutical Services, Inc., L.L.C., New Brunswick, NJ  
Address for Correspondence:  G. Lynis Dohm, Ph.D. 
     Department of Physiology 
     Brody Medical School 
     East Carolina University 
     600 Moye Blvd. 
     Greenville, NC 27834 
     Phone: 252-744-2682 
     Fax: 252-744-3460 
     E-mail: dohmg@ecu.edu 
Key words:  Gastric bypass, diabetes, hyperinsulinemia, insulin sensitivity, insulin 
secretion 
  13 
Abstract 
Roux-en-Y gastric bypass (RYGB) has been shown to induce a rapid and durable 
reversal of Type 2 diabetes. The aim of the study was to investigate a possible 
mechanism for the remission of type 2 diabetes following RYGB.  A cross sectional, 
non-randomized, controlled study was conducted.  Surgery patients were studied prior 
to RYGB and 1 week and 3 months post-surgery. This study was conducted at the 
Brody School of Medicine, East Carolina University.  Subjects were recruited into three 
groups: 1) lean [body mass index (BMI) < 25 kg/m2; n = 9]; 2) severely obese Type 2 
diabetic patients (BMI > 35 kg/m2; n = 9); and 3) severely obese non-diabetic patients 
(BMI > 35 kg/m2; n = 9).  The intervention utilized was RYGB.  One week after RYGB, 
diabetes was resolved in spite of continued insulin resistance (SI approximately 50% of 
lean controls) and reduced insulin secretion during an IVGTT (AIRg approximately 50% 
of lean controls).  Fasting insulin decreased and was no different from lean control in 
spite of continued elevated glucose in the type 2 diabetic patients compared to lean. 
After RYGB, fasting insulin decreases to levels like those of lean control subjects and 
diabetes is reversed.  This leads us to propose that 1) exclusion of food from the foregut 
corrects hyperinsulinemia and 2) fasting insulin is dissociated from the influence of 
fasting glucose, insulin resistance and BMI.  The mechanism(s) for reversal of diabetes 
in the face of reduced insulin remains a paradox.
  14 
 
INTRODUCTION 
 Our group was the first to report, in 1980, that the Roux-en-Y gastric bypass 
(RYGB), a surgical procedure used to treat severe obesity involving gastric restriction 
and bypass of the proximal small intestine, results in rapid and sustainable reversal of 
type 2 diabetes (Pories, MacDonald, Flickinger et al., 1992).  Recently, our meta-
analysis examining 621 studies confirmed that 80% of patients experience complete 
type 2 diabetes (T2DM) reversal following RYGB (Buchwald et al., 2009) and we have 
found this improvement to be sustained for at least fourteen years (Pories et al., 1995).  
In addition to the reversal of diabetes we also discovered that RYGB corrects 
hyperinsulinemia and restores insulin sensitivity in non-diabetic patients (Bikman et al., 
2008; Pories, MacDonald, Morgan et al., 1992).  Most important, these changes were 
not merely a correction of abnormal laboratory values; the operation also reduced the 
mortality of the severely obese patients by 78% (MacDonald et al., 1997). 
 Although patients lose weight following RYGB the mechanism(s) for immediate 
diabetes reversal are not likely solely due to weight loss for the following reasons.  1) 
Patients become non-diabetic within days after the surgery, before significant weight 
loss (Pories et al., 1995).  2) Neither calorically induced weight loss nor adjustable 
gastric banding, the purely restrictive bariatric surgical procedure report similar diabetes 
reversal rates (Laferrere et al., 2008).  3) In a study comparing RYGB and gastric 
banding diabetes was resolved within one week following RYGB, a rapid improvement 
not seen in the gastric banding cohort (Kashyap et al., 2010). 4) The diabetes reversal 
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rate for gastric banding is 55% and that reversal generally does not occur until 
significant weight loss is achieved (Buchwald et al., 2009). 
 We are interested in the mechanisms that are responsible for the reversal of type 
2 diabetes following gastric bypass surgery in human subjects.  Type 2 diabetes is 
traditionally characterized by insulin resistance, eventual pancreatic cell dysfunction, 
decreased insulin secretion and hyperglycemia (DeFronzo, 2004).   
 The purpose of this study was to explore the relationship of the rapid and durable 
remission of type 2 diabetes following RYGB to changes in insulin secretion and insulin 
sensitivity.  We utilized a mixed meal test to determine the role of the gut in regulating 
insulin secretion and insulin sensitivity related improvements.  In addition to clinical and 
laboratory assessment of the course of these patients, we administered an insulin 
modified intravenous glucose tolerance test to exclude the gut and determine gastric 
bypass related improvements in insulin secretion and insulin sensitivity.   
MATERIALS AND METHODS 
 A total of 27 women were studied: Nine severely obese non-diabetic and nine 
severely obese type 2 diabetic women were studied before and after Roux-en-Y gastric 
bypass surgery.  Trials were performed approximately 1 week prior to surgery and 1 
week and 3 months post surgery.  For comparison, nine lean females who did not 
undergo RYGB were also studied. 
Subjects 
  Lean (n = 9; BMI < 25 kg/m2), severely obese non-diabetic (n = 9; BMI > 40  
kg/m2) and severely obese type 2 diabetic (n = 9; BMI > 40  kg/m2). The study was 
limited to Caucasian women to exclude the influences of gender and race.  All subjects 
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were sedentary and performed normal activity with no specific exercise program.  T2DM 
patients were instructed to stop their medications 48 hours prior to the trials that were 
performed.  Patients taking thiazolidinedione (TZD) medications were excluded from the 
study.  Subjects were informed of the protocol and signed an informed consent 
document.  The protocol and consent form were approved by the East Carolina 
University and Pitt County Memorial Hospital Institutional Review Boards. 
Roux-en-Y gastric bypass surgery   
 The gastric bypass surgery was performed as described previously (Pories, 
MacDonald, Flickinger et al., 1992).  In brief, Roux-en-Y gastric bypass surgery consists 
of creation of a proximal gastric pouch of 30 cc through the partition of the stomach, a 
Roux-en-Y gastrojejunostomy with an alimentary limb of 100 cm and a bilio-pancreatic 
limb of 60 cm.  Two weeks prior to surgery, patients were put on a diet of Optifast© 800 
(Novartis Nutrition Group; Vevey, Switzerland) Ready to Drink Shakes which consists of 
35% protein, 15% fat and 50% carbohydrates for a total of 800 kcal/day.  Patients were 
instructed to consume 5 shakes per day for the 14 days prior to surgery.  For the first 
week following surgery patients were given Bariatric Advantage Meal Replacement 
(Bariatric Advantage, Irvine, CA), which consists of 150-160 kcal; protein 54%; fat 8%; 
carbohydrate 23% and instructed to consume 1 meal replacement per day.  All of the 
care was provided in a Bariatric Surgery Center of Excellence certified by the American 
Society for Metabolic and Bariatric Surgery; each of the subjects, except for the lean 
comparison group, was entered into the BOLD national database. 
Mixed Meal Test (MMT) 
 A standardized liquid meal, HiCal (150 kcal; protein, 17%; fat, 43%; 
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carbohydrate, 40%) (Abbott Laboratories, Abbott Park, IL), was given after an overnight 
fast.  A catheter was placed in an antecubital vein and blood was drawn at 10, 20, 30, 
60, 90, 120, and 180 minutes relative to the start of the meal.  Samples were treated 
with a DPP-IV Inhibitor (Millipore, Billerica, MA) and protease inhibitor cocktail 
(Complete Mini Tabs, Roche, Indianapolis, IN) immediately following the blood draws to 
prevent degradation of GLP-1.  The samples were then centrifuged and plasma was 
transferred and frozen at –80 °C for the later determination of glucose, insulin, c-peptide 
and GLP-1.  Glucose was determined by oxidation reaction (YSI model 2300 Stat Plus; 
Yellow Springs Instruments, Yellow Springs, OH).  Insulin, c-peptide and GLP-1 were 
quantified utilizing an enzyme linked immunosorbent assay (Millipore, St. Charles, MO, 
USA).  To assess how insulin secretion changes with plasma glucose, a model based 
method was used to assess beta-cell function based on a method developed by Mari et 
al (Mari, Tura, Gastaldelli, & Ferrannini, 2002) that has been used successfully to study 
effects of other treatments (Mari et al., 2007; Mari et al., 2005).  To do this, we first used 
deconvolution analysis (Van Cauter, Mestrez, Sturis, & Polonsky, 1992) to calculate the 
insulin secretion rate profile and then used linear regression to determine the 
relationship between plasma glucose concentrations and insulin secretion rate.  The 
slope of the relationship between plasma glucose and insulin secretion rate (in 
(pmol/min/m2)/(mg/dl)) is denoted as the glucose-sensitivity for insulin secretion.  
Insulin clearance was calculated as the AUC for insulin secretion (in pmol/min/m2) 
divided by the AUC of plasma insulin (in pmol/L) (Polonsky et al., 1994).  Incremental 
area under the curve (AUC) was calculated using the pre-meal values as baseline. 
Intravenous Glucose Tolerance Test (IVGTT) 
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 Initial blood samples were drawn following an overnight fast. Following the 
fasting blood samples, glucose (50%) was injected into a catheter placed in an 
antecubital vein at a dose of 0.3g/kg body mass.  Insulin, at a dose of 0.025 U/kg body 
mass was injected at min 20.  Blood samples were obtained at min 2, 3, 4, 5, 6, 8, 10, 
12, 14, 16, 19, 22, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, and 180.  Samples 
were centrifuged and plasma was aliquoted to storage tubes and frozen at –80° C for 
the subsequent determination of insulin and glucose.  Insulin was determined by 
immunoassay (Access Immunoassay System; BeckmanCoulter, Fullerton, CA) and 
glucose was determined by oxidation reaction (YSI model 2300 Stat Plus; Yellow 
Springs Instruments, Yellow Springs, OH).  Insulin sensitivity (SI) index and beta cell 
function (acute insulin response to glucose, AIRg) were assessed utilizing minimal 
modeling analysis (MinMod Millennium, Los Angeles, CA) (Bergman et al., 1985).  The 
disposition index (DI) was calculated as the product of SI and AIRg.  The homeostatic 
model assessment of insulin resistance (HOMA - IR), which is a measurement of insulin 
resistance, was calculated from fasting glucose and insulin values (fasting glucose 
mg/dL * fasting insulin µU/ml/405).   
Statistics 
 All data are shown as mean + SE.  Pre-surgery comparisons between the groups 
were made using one-way ANOVA.  Comparisons were made between type 2 diabetic 
and obese non-diabetic groups from pre-surgery, 1 week and 3 months post-surgery 
using a mixed plot factorial two-way ANOVA (Condition x Time) followed by Bonferroni 
post hoc analyses where appropriate.           
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RESULTS 
Subjects 
 Subject characteristics are reported in Table 1.  There were no differences in age 
between the diabetic and non-diabetic groups but the diabetic group was significantly (P 
< 0.05) older than the lean comparison group.  Before surgery both obese type 2 
diabetic and obese non-diabetic patients had greater body weight and BMI than lean, 
but there were no differences between diabetic and non-diabetic obese groups.  There 
was a significant effect of surgery over time on both body weight and BMI (P < 0.05), 
however weight was not different between diabetic and non-diabetic groups at either 1 
week or 3 months post-surgery.  
Fasting Metabolites 
 Fasting glucose was consistently higher in the type 2 diabetic patients at all times 
and there was a main effect of surgery to lower glucose in both groups at 1 week and at 
3 months post-surgery (P < 0.05) (Fig. 3A).  Pre-surgery fasting insulin was significantly 
higher (P < 0.05) in both the diabetic and non-diabetic groups compared to 1 week and 
3 months post surgery (Fig. 3B).  Pre-surgery fasting c-peptide was significantly higher 
(P < 0.05) in both the diabetic and non-diabetic groups compared to 1 week and 3 
months post surgery (Fig. 3C).  There was a significant time effect for fasting GLP-1, 
however post hoc analysis was unable to identify differences between time points (Fig. 
3D). 
Mixed meal test 
  In both the diabetic and non-diabetic groups it appears the kinetics of glucose 
and insulin change following RYGB.  Compared to pre-surgery, the 1-week and 3 month 
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post-surgery peak values of glucose and insulin in response to a meal test were shifted 
from 60 minutes to about 30 minutes (Figs 4A and 4B).  Both the diabetic and non-
diabetic groups experienced a more robust insulin response from baseline to peak 
following the mixed meal compared to pre-surgery.  In the non-diabetic group, the peak 
insulin response following a meal was increased approximately 20% following surgery 
(Fig. 4B) whereas the peak insulin following a meal was unchanged in the patients with 
type 2 diabetes (Fig. 4B).  Similarly, c-peptide area under the curve was significantly 
increased (P < 0.05) in the non-diabetic group following surgery and remained 
unchanged in the patients with type 2 diabetes (data not shown).  GLP-1 area under the 
curve in both the diabetic and non-diabetic groups significantly increased (P < 0.05) 
both 1 week and 3 months post-surgery (Fig. 4C).  
Insulin Sensitivity 
 There were no differences in HOMA-IR or IVGTT-assessed insulin sensitivity 
between the obese non-diabetic and lean control groups.  As morbidly obese individuals 
are typically very insulin resistant, we believe there were no differences due to the 
caloric restriction (800 kcal/day for two weeks prior to surgery) of the pre-surgery diet in 
the obese non-diabetics.  In a previous study, we found the SI of morbidly obese 
patients was only about 20% that of lean controls when they were not under dietary 
restriction (Bikman et al., 2008).  The diabetic group was on the same restricted diet 
and remained extremely hyperglycemic, hyperinsulinemic and insulin resistant.  Pre-
surgery HOMA-IR was significantly higher (P < 0.05) in the diabetic group compared to 
all other groups at all time points (Fig. 5A).  Three months post-surgery the diabetic 
group’s HOMA-IR was 1.64 + 0.54 and approached the lean control HOMA-IR value of 
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1.51 + 0.60.   This was due to significant decreases in both fasting insulin and glucose 
three months post-surgery, but at 1 week post-surgery was due primarily to a the 
significant decrease in fasting insulin.  Prior to surgery, SI was significantly lower (P < 
0.05) in the diabetic group compared to the lean group (Fig 5B) but not different when 
compared with the obese non-diabetic group.  One week following surgery, SI increased 
two-fold in the diabetic group but was still only approximately 50% of the lean group.  
Three months post-surgery the diabetic group remained approximately 40% as insulin 
sensitive as the lean controls.  There were no changes in the SI of the obese non-
diabetic group from pre to 1 week or 3 months post surgery. 
Insulin Secretion 
 The acute insulin response to glucose (AIRg) was significantly lower (P < 0.05) in 
the obese diabetic group compared to the obese non-diabetic group pre-surgery (Fig. 
5C).  Three months post-surgery in the diabetic group the AIRg was significantly 
increased (P < 0.05) (Fig. 5C).  Interestingly, the AIRg in the obese group decreased 1 
week and 3 months following surgery and the diabetic group AIRg significantly 
increased yet both groups appear to normalize to lean control values at 3 months post-
surgery.  At all time points, the disposition index was lower in the diabetic group as 
compared to the obese non-diabetic group (P < 0.05) (Fig. 5D).  Glucose sensitivity for 
insulin secretion was lower at all time points in the diabetic group compared to the 
obese group (P < 0.05) (Fig. 5E).  The change (Δ) in plasma insulin from fasting to peak 
(30 minutes) following the mixed meal test was 3-fold higher in type 2 diabetic patients 1 
week following RYBG compared to pre-surgery (Fig 5F).  At all time points, the change 
in plasma insulin was lower in the diabetic group.  Insulin clearance doubled in the type 
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2 diabetic patients from pre-surgery to 3 months post-surgery (0.46 + 0.07 L/min/m2 pre-
surgery vs. 0.93 + 0.31 L/min/m2 3 months post-surgery). There were no changes in 
insulin clearance in the obese non-diabetic group from pre to 1 week or 3 months post-
surgery (Fig 3G). 
DISCUSSION 
 Our initial purpose in performing this study was to examine changes in insulin 
secretion and insulin sensitivity to identify a potential mechanism(s) in the remission of 
type 2 diabetes.  In type 2 diabetic patients we found that insulin sensitivity and 
secretion increased one-week following surgery (Figs 5A, B, C, and E) consistent with 
previously reported data from our group and others (Bikman et al., 2008; Guidone et al., 
2006; Pories, 1992; Pories, MacDonald, Flickinger et al., 1992; Salinari et al., 2009).  It 
does not seem likely that these changes are the mechanism(s) responsible for the 
amelioration of type 2 diabetes one-week post-surgery, for the following reasons.  While 
insulin sensitivity more than doubles in patients with type 2 diabetes one week following 
surgery these patients are still profoundly insulin resistant with SI only 50% of lean 
control subjects (Fig 5B).  Likewise, insulin secretion following surgery is not normalized 
in patients with type 2 diabetes. In response to an IVGTT one week post-surgery, AIRg 
is clearly below both lean controls and obese non-diabetic patients (Fig 5C).  Similarly, 
glucose sensitivity for insulin secretion following a meal is lower in diabetic patients than 
either the lean controls or obese non-diabetic patients (Fig 5E).  Additionally, while the 
change in insulin concentration from basal to peak in response to a meal in diabetic 
patients one week after surgery is similar to lean subjects it is still lower than obese 
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non-diabetic patients (Fig 5F).  Thus, changes in insulin sensitivity and insulin secretion 
do not seem sufficient to explain the remission of type 2 diabetes. 
 Of the metabolic changes that occur after gastric bypass surgery the most 
pronounced and consistent change is a decrease in fasting insulin (Fig 3B) (Bikman et 
al., 2008; Pories, MacDonald, Morgan et al., 1992).  Plasma insulin was elevated in 
non-diabetic obese patients and even higher in diabetic patients prior to surgery, yet 
within days following surgery insulin values were within the range of normal lean control 
subjects (Kashyap et al., 2010; Pories, MacDonald, Flickinger et al., 1992).  This raises 
the counterintuitive question whether a decrease in fasting plasma insulin precedes and 
contributes to the remission of type 2 diabetes.  This concept would be compatible with 
the finding that basal-state hyperinsulinemia in healthy normoglycemic adults 
constitutes an independent risk factor for developing dysglycemia over 24 years 
(Dankner, Chetrit, Shanik, Raz, & Roth, 2009).  
 After surgery fasting insulin in diabetics was not different than lean controls, 
despite glucose being elevated by approximately 25% (Fig 6A).  This suggests that in 
diabetic patients glucose is not driving the production of insulin in the fasting state 
following RYGB. Fasting insulin is also normally elevated in insulin resistant individuals.  
Yet, one week post-surgery fasting insulin in our diabetic patients was normal, despite 
the fact that they were still obese and profoundly insulin resistant (SI was only 50% of 
lean controls).  In a similar fashion, fasting insulin is usually elevated with increasing 
BMI but our patients did not have any change in insulin between 1 week and 3 months, 
despite returning to a regular diet and having a significant decrease in BMI.  These 
changes of the relationships of fasting insulin to plasma glucose, insulin resistance and 
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BMI are also demonstrated in our previously reported data of non-diabetic post-surgery 
patients studied in a weight stable condition (Bikman et al., 2008).  Bikman et al. 
(Bikman et al., 2008) showed that for non-surgery control subjects fasting insulin was 
highly correlated with BMI, but the gastric bypass patients had insulin as low as lean 
individuals and this did not change with increasing BMI.  The same changes in the 
relationships of fasting insulin to plasma glucose and insulin sensitivity were found in 
that study but the data is not shown in a way to make the relationships apparent.  In 
Figure 6 we have redrawn the data that was previously published (Bikman et al., 2008).  
Fasting plasma insulin was lower for gastric bypass patients than controls at any 
concentration of fasting glucose (Fig 6A).  Likewise, the relationship between fasting 
insulin and insulin sensitivity was shifted to the left in gastric bypass patients, 
demonstrating lower fasting insulin for any value of insulin sensitivity (Fig 6B).  We 
believe these results suggest a paradigm shift in which the foregut plays a role in insulin 
regulation and by bypassing the proximal small intestine, such as in RYGB, it is possible 
to correct hyperinsulinemia and change the relationship between insulin and glucose, 
insulin resistance and BMI.   
 This led us to consider the significance of fasting insulin and the role it plays in 
the resolution of type 2 diabetes following surgery.  The remission of type 2 diabetes 
can be a result of either increased glucose disposal and/or a decrease in glucose 
production.  One measure of glucose disposal is area under the curve following a meal.  
Fig 6C shows there was no change in glucose AUC one-week after surgery suggesting 
that glucose disposal is not altered.  In contrast, fasting glucose was significantly 
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decreased one-week post-surgery indicating perhaps the reduction in glucose 
production is a mechanism contributing to the amelioration of type 2 diabetes.   
 Patients with type 2 diabetes experience fasting hyperinsulinemia and the 
pancreas, already working to capacity, has an inadequate capacity to secrete the 
additional amount of insulin needed for glucose disposal (Fig. 6D pre-surgery).  One 
week after surgery there is a robust increase in insulin after the meal, but this is a result 
of reduced fasting insulin with peak insulin being approximately the same before and 
after surgery (Fig 6D).  These data suggest that one-week post-surgery fasting insulin is 
decreased and the pancreas now has a greater capacity for change to regulate glucose 
disposal. 
 The significant reduction in fasting insulin most likely has significant 
consequences for insulin action in peripheral tissues as well.  In response to insulin, 
IRS-1 becomes phosphorylated on tyrosine and serine residues.  Tyrosine 
phosphorylation is the signal for insulin action (e.g., increased glucose uptake by 
peripheral tissues), but serine phosphorylation (especially on serine 307/312) causes 
insulin resistance (Itani et al., 2000; Zhou et al., 1999).  We find excessive 
phosphorylation of serine 312 on IRS-1 in muscle of obese patients before surgery but 
the level of IRS-1 serine phosphorylation in muscle of patients who have had gastric 
bypass surgery is equivalent to that of lean subjects and significantly less than of weight 
matched controls (Bikman et al., 2008).  The mechanism for the increase in insulin 
sensitivity that we observe in diabetics a week after surgery may well be a result of the 
reduction in fasting insulin which allows for the appropriate pancreatic secretion of 
insulin in response to a physiological stimulus. 
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 Our data suggest that correction of hyperinsulinemia is a primary event in 
severely obese diabetic and non-diabetic patients when they undergo RYGB.  This 
leads us to the hypothesis that exclusion of food from the foregut corrects 
hyperinsulinemia and dissociates fasting insulin from the influences of fasting plasma 
glucose, insulin resistance and BMI.  We recognize that it is counterintuitive that 
lowering fasting plasma insulin would precede and likely contribute to the remission of 
type 2 diabetes.  However, if this is correct, a paradigm shift in how we treat type 2 
diabetes may be to remove the stimulus causing hyperinsulinemia.  Further, if 
hyperinsulinemia is a central abnormality of T2DM, what is the role of insulin therapy?  
We believe the stimulus that causes hyperinsulinemia is a signal coming from the 
foregut and research in this area is warranted.  
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Table 1. Patient Demographic Information: Significance = p < 0.05  ‡ significantly 
different from lean pre surgery, ‡‡ significantly different from obese pre surgery, * main 
effect of Time – time points significantly different from all other time points.  
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    Pre 1 Week  3 Months 
Age (years)     
  Lean 34.9 + 5.1     
  Obese 37.4 + 2.6     
  Diabetic 49.1 + 2.0 ‡     
Weight (kg)         
  Lean 61.2 + 2.9     
  Obese 125.9 + 4.6 ‡ 118.8 + 4.5 * 97.1 + 3.8 * 
  Diabetic 127.6 + 6.4 ‡ 118.1 + 7.7 * 97.4 + 5.7 * 
BMI (kg/m2)         
  Lean 22.9 + 0.9     
  Obese 44.8 + 1.1 ‡ 42.3 + 1.0 * 34.3 + 1.0 * 
  Diabetic 46.6 + 2.3 ‡ 43.2 + 2.3 * 35.5 + 1.9 * 
HbA1C         
  Lean      
  Obese 5.3 + 0.2     
  Diabetic 8.7 + 0.5 ‡‡     
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Figure 3. Fasting glucose (A) (n = 9 lean, n = 8 obese and T2DM) insulin (B) (n = 8 lean, 
n = 8 obese and T2DM), C-peptide (C) (n = 9 lean and n = 8 obese and T2DM) and 
GLP-1 (D) (n = 9 lean, n = 8 obese and n = 6 T2DM) pre-surgery and 1 week and 3 
months post-surgery. In D, there was a significant main effect of time but post-hoc 
analysis did not determine a difference. The mean + SEM for the lean control group is 
represented by the solid and dashed lines. * significantly different from lean and obese 
pre-surgery, # significantly different from lean pre-surgery. 
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A.          B. 
C.       D. 
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Figure 4. Changes in glucose (A), insulin  (B) and GLP-1 (C) in response to a mixed 
meal tolerance test in lean, obese (pre-surgery, 1-week post-surgery and 3 months post 
surgery) and diabetic (pre-surgery, 1-week post-surgery and 3 months post-surgery) 
subjects. * pre-surgery area under the curve significantly different than 1 week and 3 
months post-surgery. For lean patients n = 9 in all data sets. Pre-surgery obese n = 9 
with the exception of GLP-1, n = 6. 1 week post-surgery obese n = 9 for all except GLP-
1, n = 8. 3 months post-surgery obese n = 8 with the exception of GLP-1, n = 7. For all 
measurements in the T2DM, n = 10 pre-surgery and 1 week post-surgery and n = 8 3 
months post-surgery. 
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Figure 5. HOMA- IR (A), SI (B), AIRg (C), and Disposition Index (D) in lean, obese and 
diabetic patients pre surgery, 1-week and 3-months post surgery in response to an 
IVGTT. Glucose sensitivity (E), basal (0 time) to peak (30 minutes) change (Δ) in 
plasma insulin (F) and insulin clearance (G) in lean, obese and diabetic patients pre-
surgery, 1-week and 3-months post-surgery in response to a mixed meal. * significantly 
different than lean and obese pre-surgery, # significantly different than lean pre-surgery 
and ** significantly different than obese pre-surgery.   
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Figure 6. The relationship of fasting insulin to fasting glucose (A) and insulin sensitivity 
(B) in normal subjects (open circles) and non-diabetic gastric bypass patients (closed 
squares) who have lost weight and are weight stable. Redrawn from data previously 
published (Bikman et al., 2008).  Glucose area under the curve (AUC), fasting glucose 
and fasting insulin in type 2 diabetic patients pre-surgery and 1 week and 3 months 
post-surgery (C).  Plasma insulin in response to a mixed meal in type 2 diabetic patients 
pre-surgery and 3 months post-surgery (D). 
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Abstract 
Approximately 80% of Type 2 diabetics exhibit complete reversal of diabetes following 
gastric bypass surgery.  The purpose of this study was to examine potential 
mechanisms that allow some patients to respond to gastric bypass while others do not. 
Roux-en-Y gastric bypass (RYGB) was performed in eight severely obese (BMI > 40) 
diabetic Caucasian women.  Both an insulin-modified intravenous glucose tolerance test 
(IVGTT) and mixed meal tolerance test (MMTT) were performed prior to and 1 week 
and 3 months post surgery. At 3-months post-RYGB, three of the diabetic patients had 
complete diabetes resolution as defined by fasting plasma glucose (FPG) below 100 
mg/dl without diabetic medication (Responders [R]: FPG 90.2 + 6.5 mg/dl), three 
patients exhibited impaired fasting glucose (FPG: 106 + 2 mg/dl) and two patients 
remained diabetic (Non responders [NR]: 174.2 + 34.7 mg/dl). The pre-RYGB 
characteristics that were correlated with 3-mo post-RYGB FPG were duration of 
diabetes (r = 0.7450, p = 0.0339) and insulin sensitivity (SI) obtained from the IVGTT  (r 
= -0.7799, p = 0.0386).  These data suggest that pre-RYGB insulin sensitivity may be a 
predictor of Type 2 diabetes resolution following RYGB.  
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INTRODUCTION 
 Roux-en-Y gastric bypass (RYGB) has been shown to be both a rapid and 
durable method for reversing type 2 diabetes mellitus in severely obese individuals 
(Pories et al., 1995).  It has been reported that 80% of type 2 diabetics that undergo 
RYGB experience complete resolution of the disease following surgery (Buchwald et al., 
2009).  Possible mechanisms for the amelioration of type 2 diabetes following RYGB 
include restoration of insulin sensitivity and secretion, weight loss and changes in gut 
hormones due to the rearrangement of the gastrointestinal tract (Ferrannini & Mingrone, 
2009; Rubino & Marescaux, 2004; Whitson et al., 2007). 
 Little is known regarding the approximately 20% of type 2 diabetic patients that 
do not respond to RYGB although it appears that duration and severity of the disease 
are two factors that contribute to the resolution of type 2 diabetes following surgery 
(Buchwald et al., 2004; Buchwald et al., 2009).  Recently, reports have indicated that 
glycosylated hemoglobin (HbA1c), fasting plasma glucose, body mass index (BMI) and 
the presence of the co-morbidity hypertension may also affect diabetes resolution 
following RYGB (Hall, Pellen, Sedman, & Jain, 2010; Hayes, Hunt, Foo, Tychinskaya, & 
Stubbs, 2011). 
 We are interested in determining the mechanism(s) why the majority of T2DM 
patients improve their diabetes following RYGB while some do not.  As T2DM is a 
progressive disease, clinically it is imperative to counsel patients on the best options for 
their treatment.  If it is possible to determine what pre-surgery characteristics are 
favorable for remission of T2DM, clinicians will be better able to recommend appropriate 
treatment.  To date, the majority of reports have identified pre-RYGB descriptive factors 
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that are associated with the reversal of T2DM post-RYGB (Buchwald et al., 2004; 
Buchwald et al., 2009; Hall et al., 2010; Hayes et al., 2011).  It has consistently been 
reported that both duration and severity of T2DM are associated with poor outcomes 
following RYGB, however, it is not known whether this is due to a decrease in 
pancreatic function, peripheral insulin sensitivity or a combination of the two.  The 
purpose of this study was to elucidate potential mechanisms that could be predictive of 
T2DM resolution post-RYGB. 
MATERIALS AND METHODS 
 Our original study was conducted in order to determine changes in insulin 
sensitivity and secretion one week and three months following RYGB in severely obese 
type 2 diabetic and non- diabetic women (Reed et al., 2011).  We then examined our 
original cohort of participants and grouped them into one of three categories; 
responders, defined by fasting plasma glucose < 100 mg/dL three months post-RYGB 
without anti-diabetic medication; impaired, defined by fasting plasma glucose between 
100 mg/dL and 124 mg/dL three months post-RYGB; or non-responders, defined by 
fasting plasma glucose > 125 mg/dL three months post-RYGB.  Following the 
classification of the patients into one of three groups we then sought to identify the 
factors related to Type 2 diabetes amelioration following RYGB. 
Subjects 
 This study included severely obese type 2 diabetic (n = 8) women. Subject 
characteristics are in Table 1.  The study was limited to Caucasian women to exclude 
the influences of gender and race.  All subjects were sedentary and performed normal 
activities of daily living with no specific exercise program.  Patients were instructed to 
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stop their medications 48 hours prior to the trials that were performed and patients 
taking thiazolidinedione (TZD) medications were excluded from the study.  Participants 
were informed of the protocol and signed an informed consent document.  The protocol 
and consent form were approved by the East Carolina University and Pitt County 
Memorial Hospital Institutional Review Board. 
Roux-en-Y gastric bypass surgery 
 The gastric bypass surgery was performed as described previously (Pories, 
MacDonald, Flickinger et al., 1992).  Briefly, RYGB consists of the creation of a proximal 
gastric pouch of 30 cc through the partition of the stomach, a Roux-en-Y 
gastrojejunostomy with an alimentary limb of 100 cm and a bilio-pancreatic limb of 60 
cm.  Two weeks prior to surgery, patients were put on a diet of Optifast© 800 (Novartis 
Nutrition Group; Vevey, Switzerland) Ready to Drink Shakes which consists of 35% 
protein, 15% fat and 50% carbohydrates for a total of 800 kcal/day.  Patients were 
instructed to consume 5 shakes per day for the 14 days prior to surgery.  For the first 
week following surgery patients were given Bariatric Advantage Meal Replacement 
(Bariatric Advantage, Irvine, CA), which consists of 150-160 kcal; protein 54%; fat 8%; 
carbohydrate 23% and instructed to consume 1 meal replacement per day.  All of the 
care was provided in a Bariatric Surgery Center of Excellence certified by the American 
Society for Metabolic and Bariatric Surgery and each subject was entered into the 
Bariatric Outcomes Longitudinal Database (BOLD) national database. 
Mixed Meal Test (MMT) 
 A standardized liquid meal, HiCal (150 kcal; protein, 17%; fat, 43%; 
carbohydrate, 40%) (Abbott Laboratories, Abbott Park, IL), was given after an overnight 
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fast and patients were instructed to consume the meal within 10 minutes.  A catheter 
was placed in an antecubital vein and blood was drawn prior to the meal and at 10, 20, 
30, 60, 90, 120, and 180 minutes relative to the start of the meal.  Samples were treated 
with a protease inhibitor cocktail (Complete Mini Tabs, Roche, Indianapolis, IN) 
immediately following the blood draws.  The samples were centrifuged and plasma was 
transferred and frozen at –80 °C for the later determination of glucose and insulin.  
Glucose was determined by oxidation reaction (YSI model 2300 Stat Plus; Yellow 
Springs Instruments, Yellow Springs, OH) and insulin was quantified utilizing an enzyme 
linked immunosorbent assay (Millipore, St. Charles, MO, USA).   
Intravenous Glucose Tolerance Test (IVGTT)   
 Initial blood samples were drawn following an overnight fast. Following the 
fasting blood samples, glucose was injected into a catheter placed in an antecubital vein 
at a dose of 0.3g/kg body mass.  Insulin, at a dose of 0.025 U/kg body mass was 
injected at min 20.  Blood samples were obtained at min 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 
19, 22, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, and 180.  Samples were 
centrifuged and plasma was aliquoted to storage tubes and frozen at –80° C for the 
subsequent determination of insulin and glucose.  Insulin was determined by 
immunoassay (Access Immunoassay System; BeckmanCoulter, Fullerton, CA) and 
glucose was determined by oxidation reaction (YSI model 2300 Stat Plus; Yellow 
Springs Instruments, Yellow Springs, OH).  Insulin sensitivity (SI) index and beta cell 
function (acute insulin response to glucose, AIRg) were assessed utilizing minimal 
modeling analysis (MinMod Millennium, Los Angeles, CA) (Bergman et al., 1985).  The 
homeostatic model assessment of insulin resistance (HOMA - IR), which is a 
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measurement of insulin resistance, was calculated from fasting glucose and insulin 
values (fasting glucose mg/dL * fasting insulin µU/ml/405)(Emoto et al., 1999).   
Statistics 
 Data are shown as the both absolute and relative change from pre to 3-mo post-
RYGB.  Linear regression was preformed to investigate associations between fasting 
blood glucose three months post-RYGB and 1.) SI pre-surgery, 2.) duration of diabetes 
pre-RYGB, 3.) BMI pre-RYGB and 4.) HbA1c pre-RYGB.  A priori we chose the pre-
RYGB variables duration of diabetes (Schauer et al., 2003), BMI (Hayes et al., 2011), 
and HbA1c (Hall et al., 2010) based on previous reports that have found associations 
between these factors and remission of T2DM.  Recently, glucose disposition index, a 
product of insulin sensitivity and beta cell function, has also been reported to influence 
reversal of T2DM following RYGB (Perugini & Malkani, 2011).  However, insulin 
sensitivity and beta cell function have not been examined separately as potential 
predictors of T2DM remission following RYGB.  We examined these factors when 
determining associations between both SI pre-RYGB and AIRg (as a measure of beta 
cell function) pre-RYGB and fasting blood glucose three months post-RYGB.  This was 
done to determine potentially predictive factors in the resolution of Type 2 diabetes 
following RYGB. 
RESULTS 
 Following RYGB, we found that the pre-RYGB factors significantly correlated with 
3-mo post-RYGB FPG (as a measure of diabetes resolution) were insulin sensitivity (r = 
-0.7799, p=0.0386) and duration of diabetes (r = 0.7450, p=0.0339) (Figures 7A and 
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1B). There was no correlation between 3-mo post-RYGB fasting glucose and pre-RYGB 
BMI, HbA1c, or AIRg (Figures 7C, 1D and 1E).    
 Three months post-RYGB, three of the patients had complete diabetes resolution 
with fasting plasma glucose < 100 mg/dL and no diabetic medication usage as the 
criteria for resolution (Responders [R]: FPG=90.2+6.5 mg/dl), three patients exhibited 
impaired fasting glucose (FPG=106+2 mg/dl) two remained diabetic (Non responders 
[NR]: FPG=174.2+34.7 mg/dl) (Table 2).  Pre-RYGB FPG and glucose AUC and insulin 
secretion from the MMT were similar between the R and NR and post-RYGB weight 
loss was approximately 20% for both the R and NR.   
 Fasting insulin was 70% higher in the R compared to the NR pre-RYGB but 3-mo 
post surgery fasting insulin decreased by 81% in the R and by 36% in the NR (Table 2).  
Insulin secretion in response to a meal was increased in both groups as the R exhibited 
a 20% increase and the NR had an 86% increase three months post-surgery (Table 2). 
Similarly, the AIRg for both groups increased from pre to 3-mo post-surgery with the R 
increasing by 82% and the NR increasing by 62% (Table 2).  The responders 
consistently exhibited higher SI pre and post-RYGB and while SI increased 50% in NR it 
was still only 25% that of R at 3-mo post-RYGB (Table 2).  HOMA-IR decreased in the 
R by 91% and 70% (Table 2).  
DISCUSSION 
 The central finding in this study was uncovering the positive correlation between 
insulin sensitivity pre-RYGB and fasting blood glucose three months post-RYGB.  This 
indicates the potential predictive value of insulin sensitivity in regards to diabetes 
resolution following RYGB.  We also identified duration of T2DM is a negative predictor 
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of T2DM resolution following RYGB which is in agreement with other recent literature 
(Pories, MacDonald, Morgan et al., 1992; Schauer et al., 2003).  In contrast to other 
studies, we did not see a correlation between FPG three months post-RYGB (as a 
measure of diabetes resolution) and pre-RYGB BMI or HbA1c (Hayes et al., 2011; 
Schauer et al., 2003). 
 The American Diabetes Association reports that approximately 20 million 
Americans are afflicted with T2DM and this number is expected to increase to 
approximately 40 million by 2050 ("Economic costs of diabetes in the U.S. In 2007," 
2008).  Patients with T2DM are at an increased risk for both macro and microvascular 
complications such as heart disease, nephropathy and retinopathy and T2DM is the fifth 
leading cause of mortality ("Economic costs of diabetes in the U.S. In 2007," 2008).  
Maintaining optimal glycemic control is imperative in managing and treating patients 
with T2DM.  Currently, an HbA1c < 7% is considered optimal because it is associated 
with decreased microvascular complications and optimal fasting blood glucose is 
between 70-130 mg/dl ("Standards of medical care in diabetes--2011,").  However, only 
approximately 37% of previously diagnosed T2DM patients achieved an HbA1c < 7% 
when utilizing a combination of pharmaceutical therapies including oral hypoglycemics 
and insulin therapy (Saydah, Fradkin, & Cowie, 2004). 
 T2DM is a progressive disease and becomes increasingly difficult to control 
pharmaceutically over time.  By contrast, T2DM is rapidly and durably reversed in the 
majority of patients who undergo RYGB.  It has been reported that following RYGB 
approximately 80% of patients have complete resolution of T2DM, defined as no longer 
requiring anti-diabetic medication, and 86.6% exhibit either complete resolution of 
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T2DM or an improvement in T2DM (Buchwald et al., 2009).  Moreover, we have 
reported diabetes resolution sustained for fourteen years indicating the long-term 
success of RYGB in ameliorating T2DM (Pories et al., 1995). 
 Although approximately 15% of T2DM patients do not experience any diabetes 
improvement following RYGB, there does not appear to be one mechanism that solely 
contributes to the lack of T2DM resolution in the current cohort.  Based on our study it 
appears that insulin sensitivity prior to surgery could be of great predictive value in 
determining the course of treatment for T2DM patients considering RYGB.  Remarkably, 
it has recently been reported that patients that undergo RYGB experience greater 
insulin sensitivity when compared to a weight matched group placed on a hypocaloric 
diet that has the same amount of weight loss (Plum et al., 2011). Additionally, we have 
previously reported that regardless of weight post-RYGB, both insulin sensitivity and 
glucose transport are increased in weight stable post-RYGB patients compared to their 
weight-matched non-RYGB counterparts (Bikman et al., 2008) indicating RYBG elicits a 
weight-independent mechanism increasing SI.  The novel finding of the increase in SI in 
the R compared to the NR both pre and post-RYGB (Table 2) indicates a potential 
predictive factor of T2DM following RYGB.   
 Conversely, our study suggests that insulin secretion may not be a predictive 
factor in the resolution of T2DM following RYGB as the NR had similar if not potentially 
greater insulin secretion (AIRg) pre-operatively compared to the R (Table 2).  These 
results are in contrast to the recent report in which β cell function appeared to be a 
potential predictor of T2DM resolution following RYGB (Perugini & Malkani, 2011).  This 
possible discrepancy could be addressed by the different testing that was done in order 
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to assess beta cell function.  In our study, an insulin-modified IVGTT was performed 
which gives a measure of endogenous insulin production in response to an IV glucose 
bolus whereas Perugini, et. al assessed beta cell reserve utilizing HOMA-B (a measure 
of beta cell function based on fasting insulin and glucose) and HOMA-S (a measure of 
insulin sensitivity based on fasting insulin and glucose) (Perugini & Malkani, 2011).  In 
addition, we administered a liquid, oral mixed meal in order to determine insulin 
secretion in response to a meal and consistent with the insulin modified IVGTT data it 
appears the NR have as good of a response as the R (Table 2).  This suggests that 
pancreatic function is not the limiting factor in the remission of T2DM following RYGB as 
the NR exhibit an 86% increase in insulin AUC following RYGB indicating that perhaps 
there is β cell reserve in this cohort of T2DM patients. 
 In both groups, insulin resistance (HOMA-IR) decreases 1 week and 3 months 
following RYGB (Table 2).  This is due to the decrease in fasting glucose and insulin in 
both groups (Table 2) in accordance with other reports (Pournaras et al., 2010; Umeda 
et al., 2011).  In R fasting glucose decreased by 55% and fasting insulin decreased by 
81% 3-mo following RYGB.  The NR experienced a modest decrease of 15% in fasting 
glucose from pre to post-RYGB and a 36% decrease in fasting insulin from pre to 3-mo 
post-RYGB.  Interestingly, the R fasting insulin pre-RYGB was 55% higher than the NR 
and 3-mo post RYGB the fasting insulin in the R was 17% less than the NR which 
suggests that the endogenous production of insulin is not a problem in this cohort.  
Rather, from this study it appears that pre-RYGB insulin sensitivity could be a potential 
mechanism in the remission of T2DM following RYGB (Table 2 and Figure 7). 
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 This study highlights the importance of maintaining peripheral insulin sensitivity.  
The predictive value of pre-RYGB insulin sensitivity could be of great value to clinicians 
in determining the appropriate treatment for patients.  Measuring insulin sensitivity prior 
to surgery could offer insight as to the potential reversal of T2DM following surgery and 
thus influence the type of surgery chosen.  The remission rates for more invasive 
malabsorptive procedures such as the bilio-pancreatic diversion (BPD) and bilio-
pancreatic diversion with duodenal switch (BPD-DS) are approximately 95% (Buchwald 
et al., 2009).  Those patients that have decreased insulin sensitivity may benefit from 
the BPD or BPD-DS and have greater improvement in their T2DM. 
 We acknowledge the small subset of patients utilized for this report.  However, 
these data are the first to indicate insulin sensitivity as a pre-operative factor related to 
reversal of T2DM.    Clinically, being able to predict potential remission of T2DM based 
on pre-operative measures could be beneficial in determining course of treatment for 
patients seeking bariatric surgery primarily for T2DM management.  Additionally, in 
determining potential predictive factors of T2DM resolution it may be possible to 
discover the mechanism(s) ultimately responsible for the successful reversal of T2DM 
following RYGB. 
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Table 2.  Anthropometric parameters, fasting plasma hormone levels and IVGTT and 
MMT values for T2DM responders and non responders. 
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  Pre-RYGB 
3 months post-
RYGB 
Δ from pre to 
post-RYGB 
% change from pre 
to post-RYGB 
Age (years)      
 Responders 47.3 + 2.2    
 Non Responders 54.4 + 4.0    
Weight (kg)      
 Responders 125.3 + 5.5 97.3 + 7.7 - 28.0 23% ↓ 
 Non Responders 139.5 + 15.5 111.5 + 17.5 - 28.0 20% ↓ 
BMI (kg/m2)      
 Responders 46.7 + 0.4 36.2 + 1.8 - 10.5 23% ↓ 
 Non Responders 52.8 + 3.2 41.7 + 4.0 - 11.1 21% ↓  
HbA1c (%)      
 Responders 9.1 + 0.9    
 Non Responders 8.3 + 1.3    
      
Fasting Glucose 
(mg/dl) Responders 199.0 + 35.1 90.2 + 6.5 
 
- 108.8 55% ↓ 
 Non Responders 205.6 + 96.4 174.2 + 34.7 - 31.4 15% ↓ 
      
Fasting Insulin 
(pmol/l) Responders 332.7 + 113.8 98.1 + 15.1 
 
- 234.6 81% ↓ 
 Non Responders 184.7 + 15.0 118.0 + 2.5 - 66.7 36% ↓ 
      
HOMA - IR Responders 10.7 + 2.0 1.2 + 0.3 - 9.5 91% ↓ 
 Non Responders 16.4 + 5.6 4.9 + 0.3 - 11.5 70% ↓ 
      
SI (min-1/µU/ml) Responders 1.1 + 0.2 1.6 + 1.0 + 0.5 32% ↑ 
 Non Responders 0.2 + 0.2 0.4 + 0.2 + 0.2 50% ↑ 
      
AIRg (µU/ml) Responders 53.6 + 29.1 293.4 + 146.6 + 239.8 82% ↑ 
 Non Responders 82.6 + 104.9 217.9 + 154.1 + 135.3 62% ↑ 
      
MMT Glucose 
AUC Responders 2,926.0 + 812.2 1,820.0 + 576.4 
 
- 1,106.0 48% ↓ 
 Non Responders 2,619.2 + 1,900.9 3,506.0 + 628.0 + 886.8 26% ↑ 
      
MMT Insulin 
AUC Responders 6,373.7 + 1,550.7 7,951.0 + 2,501.8 
 
+ 1,577.3 20% ↑ 
 Non Responders 4,011.5 + 149.5 16,519.0 + 5,188.0 + 12,507.5 86% ↑ 
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Figure 7.  Correlations between FPG three months post-surgery and pre-surgery insulin 
sensitivity (A) duration of diabetes (B), BMI (C), HbA1c (D) and AIRg (E).  
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Abstract 
Skeletal muscle is the principle site for insulin stimulated glucose uptake and primary 
human skeletal muscle cell cultures have been shown to be an effective system to 
elucidate potential mechanisms that contribute to insulin resistance.  The purpose of 
this study was to determine if exposure to chronic hyperinsulinemia would down-
regulate the insulin signaling pathway in skeletal muscle myocytes from lean insulin 
sensitive and obese insulin resistant individuals.  This study also examined the effects 
of chronic hyperinsulinemia on mitochondrial content and fatty acid oxidation.  Insulin 
signaling, mitochondrial content and fatty acid oxidation were measured in myotubes 
pooled from lean insulin sensitive and obese insulin resistant individuals following a 4 
day incubation of either low (80 pM) insulin or high (5000 pM)) insulin.  Insulin signaling 
was not down-regulated due to chronic hyperinsulinemia in either group.  Rather, 
AS160 was increased in the lean group after chronic hyperinsulinemia.  Complete 
oxidation of FA was significantly reduced and incomplete oxidation was significantly 
higher in the obese group compared to the lean group independent of insulin incubation.  
In the current study, mitochondrial content was not different between the lean and 
obese groups for either insulin condition.  Chronic hyperinsulinemia increases insulin 
signaling in lean insulin sensitive myocytes compared to obese suggesting the obese 
exhibit a blunted response.  Also, chronic hyperinsulinemia did not affect fatty acid 
oxidation or mitochondrial content in the lean or obese group but the obese group 
experienced dysregulated fatty acid metabolism independent of insulin suggesting an 
inherent defect in the obese compared to the lean group.  
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INTRODUCTION 
 Skeletal muscle is the main site of insulin-mediated glucose uptake and is also 
the principal site for peripheral insulin resistance (Shulman et al., 1990).  Insulin 
resistance and obesity related metabolic disorders, such as Type 2 diabetes, are 
associated with metabolic perturbations including mitochondrial dysfunction, 
inappropriate fatty acid metabolism and decreased insulin signaling (Bikman et al., 
2010; Kelley & Goodpaster, 1999; Kim, Hickner, Cortright, Dohm, & Houmard, 2000; 
Ritov et al., 2005).   
 Recently, we reported that Roux-en-Y gastric bypass (RYGB) reverses 
hyperinsulinemia in severely obese non-diabetic and Type 2 diabetic (T2DM) women 
within one-week of surgery even though fasting glucose levels were not completely 
normalized to lean control levels (Reed et al., 2011).  The reversal of hyperinsulinemia 
following RYGB is clinically relevant because hyperinsulinemia and metabolic disease 
are implicated with increases in cardiovascular disease and all-cause mortality (Mottillo 
et al., 2010).  
 Hyperinsulinemia may also be detrimental for skeletal muscle insulin sensitivity.   
Insulin can independently cause insulin resistance, whether administered exogenously 
(Samuelsson et al., 2006) or through an insulin infusion (Rizza, Mandarino, Genest, 
Baker, & Gerich, 1985) implicating hyperinsulinemia as a potential cause of peripheral 
insulin resistance.  In primary skeletal muscle cells isolated from both lean and T2DM 
individuals, hyperinsulinemia decreases glucose transport (Ciaraldi, Abrams, Nikoulina, 
Mudaliar, & Henry, 1995).  These data indicate that perhaps independent of blood 
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glucose, hyperinsulinemia could lead to a down-regulation of the insulin signaling 
pathway. 
  Severely obese individuals have decreased rates of complete fatty acid oxidation 
(Bell et al., 2010; Consitt et al., 2010), and increased incomplete fatty acid oxidation has 
been associated with insulin resistance (Koves et al., 2008).  Decreased fatty acid 
oxidation in obese individuals has been reported at the whole body level (Guesbeck et 
al., 2001), in muscle homogenates (Kim et al., 2000) and in primary human skeletal 
muscle cell culture (Bell et al., 2010).  Further, in primary human skeletal muscle cell 
culture, our laboratory reported that exposure to lipid decreased fatty acid oxidation and 
concomitantly decreased insulin sensitivity in myotubes from lean individuals to levels 
similar to cells from obese indicating that lipid incubation can cause the lean cells to 
exhibit responses that are similar to the obese cells (Bell et al., 2010).   
 The relationship between skeletal muscle mitochondria and insulin resistance is 
complex and contradictory.  Skeletal muscle mitochondria are the primary site for fatty 
acid oxidation and have been implicated in the pathogenesis of insulin resistance as 
decreased oxidative capacity relative to glycolytic capacity has been reported in obese 
insulin resistant women (Simoneau, Colberg, Thaete, & Kelley, 1995).  Additionally, it is 
has been shown that obesity is associated with decreased mitochondrial content 
(Consitt et al., 2010).  Conversely, reports have also shown that skeletal muscle 
mitochondria content increases in high fat fed insulin resistant rats (Hancock et al., 
2008).  Further, a recent clinical trial has demonstrated that mitochondrial capacity and 
insulin action, while related in an insulin resistant population, are not associated in 
individuals with Type 2 Diabetes that underwent a hyperinsulinemic-euglycemic clamp 
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(Bajpeyi et al., 2011).  It is not known how hyperinsulinemia directly affects skeletal 
muscle mitochondrial content and fatty acid oxidation.   
 In the present study we investigated if chronic exposure to hyperinsulinemia 
alters insulin signaling, mitochondrial content and fatty acid oxidation.  In doing this, we 
have attempted to recapitulate physiological hyperinsulinemia in primary myotubes.  It 
was hypothesized that chronic exposure to hyperinsulinemia would down-regulate 
insulin signaling in myotubes from both lean and obese.  Further, we hypothesized that 
mitochondrial content and fatty acid oxidation would be depressed in the cells from 
obese insulin resistant individuals compared to cells from the lean insulin sensitive 
individuals based on previous literature from our laboratory (Consitt et al., 2010).    
MATERIALS AND METHODS 
Subjects 
Lean insulin sensitive (n=4) (LN) and severely obese insulin resistant (n=4) (OB) 
Caucasian women were recruited for participation in this study.  Insulin resistance was 
determined by the homeostatic model assessment of insulin resistance (HOMA - IR), 
which was calculated from fasting glucose and insulin values (fasting glucose mg/dL * 
fasting insulin µU/ml/404) (Emoto et al., 1999).  All subjects were considered sedentary 
and in good health after completion of a medical history questionnaire.  Participants 
were informed of potential risks associated with the study and signed an informed 
consent document before the study began.  The protocol and consent form were 
approved by the East Carolina University Institutional Review Board. 
Primary Human Skeletal Muscle Culture 
  59 
Following a 12-h overnight fast, approximately 50-100 mg of skeletal muscle from the 
vastus lateralis of subjects was obtained by percutaneous biopsy (Evans, Phinney, & 
Young, 1982).   The isolation and culturing of human primary skeletal muscle cells from 
biopsies was performed as previously described (Muoio et al., 2002).  In brief, 
approximately 30 – 50 mg of muscle sample was transferred to cold low-glucose 
Dulbecco's modified Eagle's medium [DMEM; media and media supplements were 
purchased from GIBCO (Invitrogen, Carlsbad, CA)] and all visible connective and 
adipose tissue was removed before culture.   Satellite cells were isolated by trypsin 
digestion, pre-plated for 1–3 h in 3.0 ml of growth media (GM) [low-glucose DMEM 
supplemented with 10% FBS, 0.5 mg/ml BSA, 0.4 mg/ml fetuin, 20 ng/ml human 
epidermal growth factor, 0.39 µg/ml dexamethasone, and 40 µg/ml 
gentamicin/amphotericin B (Lonza, Walkersville, MD)] on an uncoated T-25 tissue 
culture flask (Fisher Scientific, Waltham, MA) in order to remove fibroblasts, and then 
transferred to a type I collagen-coated T-25 flask for myoblast adherement.  Cultures 
were maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% O2.  After 
reaching ~80% confluence, myoblasts were trypsinized and transferred to a type I 
collagen-coated T-75 flask.  After again reaching ~80% confluence, myoblasts from lean 
and obese subjects were separately pooled by adding roughly 100 × 103 cells/sample in 
a lean or obese cell pool, as previously reported (Bikman et al., 2010).  After the pooled 
cells reached ~80% confluence, myoblasts were then subcultured onto six- and 24-well 
type I collagen-coated plates at densities of 80 and 20 × 103 cells per well, respectively.  
After achieving ~90% confluence, differentiation was induced by replacing GM with low-
serum differentiation media (DMEM, 2% heat-inactivated horse serum, 0.5 mg/ml BSA, 
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0.5 mg/ml fetuin, and 50 µg/ml gentamicin/amphotericin B).  Media was changed every 
day and on day 3 of differentiation, media was supplemented with low insulin (80 pmol/l) 
or high insulin (5,000 pmol/l).  All human myotube cellular experiments were performed 
on day 7 of differentiation.  Therefore, all isolated cells were exposed to 4 days of low or 
high (hyperinsulinemia) insulin. 
Fatty Acid Oxidation 
On day 7, fatty acid oxidation assays were performed after a 3-h incubation in sealed 
24-well plates at 37° C in differentiation media, 12.4 mm HEPES, 0.5% BSA, 1 mm 
carnitine, 250 µm sodium oleate and 1 µCi/ml [1-14C] oleate (Sigma-Aldrich, St. Louis, 
MO).  After the incubation period, the medium was transferred to new plates and 
assayed for the collection of 14CO2 production (complete oleate oxidation), which was 
quantified via liquid scintillation counting using 4 ml of Uniscint BD (National 
Diagnostics, Atlanta, GA).  Incomplete oxidative products (acid-soluble metabolites, 
ASM’s) were also measured as previously described (Muoio et al., 2002).  The results 
are reported as a ratio between incomplete (acid-soluble metabolites) and complete (1-
14CO2) radiolabeled products.  Following the fatty acid oxidation assay, cells were 
washed twice with ice-cold PBS and harvested in 600 µl 0.05% sodium dodecyl sulfate 
(SDS) and cell lysates were stored at -80 C for subsequent protein determination. 
Insulin signal transduction via Western Blotting 
Insulin signal transduction and mitochondrial content were determined in cultured 
muscle cells from lean and obese individuals following a 4d incubation of low insulin or 
high insulin.  For insulin signaling, following the 4d incubation, cells were serum starved 
for 5 h, acutely insulin stimulated (100 nm porcine insulin) (Sigma-Aldrich) for 15 min, 
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and immediately harvested in 100 µl of ice-cold lysis buffer containing 50 mM HEPES, 
100 mM sodium fluoride, 50 mM sodium pyrophosphate, 10 mM sodium orthovanadate, 
10 mM EDTA, 1% Triton X-100, and protease and phosphatase (1 and 2) inhibitor 
cocktails (Sigma, St. Louis, MO) per well, and sonicated for 5 s, followed by a 10 minute 
spin at 20,000g at 4°C and individual protein concentrations from the cell lysates were 
determined using a bicinchoninic acid (BCA) assay kit (Pierce, Rockford, IL).  Cellular 
protein (10 µg) was separated by SDS-PAGE using Tris·HCl gels, transferred to 
nitrocellulose membranes, and then probed overnight for either pan-akt (Santa Cruz 
Biotechnology, Santa Cruz, CA) phospho akt (Thr308), phospho AS160 (Thr642), or pan 
AS160 all from Cell Signaling Technologies (Beverly, MA) and diluted in 5% BSA using 
Tris-buffered saline (TBST) with 0.1% Tween.  Phosphoproteins were normalized to 
total protein for both Akt and AS160 quantification.  Following incubation with primary 
antibodies, all blots were incubated with appropriate horseradish peroxidase-conjugated 
secondary antibodies.  Horseradish peroxidase activity was assessed with enhanced 
chemiluminescence solution (Thermo Scientific, Rockford, IL) and developed utilizing 
ImageLab (BioRad). 
Mitochondrial COXIV and Citrate Synthase   
Cytochrome C oxidase (COX)IV  and citrate synthase were measured from cells 
incubated in insulin for 4 days but without the acute 15 minute 100nM insulin 
stimulation.   For mitochondrial measurements cells were harvested from 6-well plates 
in ice-cold buffer containing 100mM KH2PO4, 2mM EDTA, 0.1% Triton X-100, pH 7.2 
and total protein was assessed using the BCA protein assay (Pierce, Rockford, IL) and 
COXIV was probed by following the technique described above.  The COXIV antibody 
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was purchased from Cell Signaling Technologies (Beverly, MA) and normalized to actin 
as a loading control.  For the citrate synthase assay, 10µg protein were loaded to all 
sample wells and citrate synthase activity was determined using a commercially 
available kit from Sigma (Sigma-Aldrich).  Citrate synthase activity was determined by 
measuring the formation of 5-thio-2-nitrobenzoic acid spectrophoetrically at 412 nm.   
Statistics   
Data are presented as Means ± SE.  Data were analyzed using a 2x2 (group x [insulin]) 
mixed plot factorial ANOVA.  After a significant F ratio, post hoc analysis was performed 
using the Bonferroni test.  Linear regression was performed to determine the 
association between citrate synthase activity and COXIV.  Significance was set at P < 
0.05. 
RESULTS 
Subjects   
There was no significant difference between lean and obese groups for age (lean; 28.3 
+ 2.1 vs. obese 33.5 + 4.3).  By design, groups were significantly different in BMI (lean; 
23.0 + 1.7 kg/m2 vs. obese; 41.4 + 3.8 kg/m2) and HOMA-IR (used as an indicator of 
insulin resistance) (lean; 1.3 + 0.3 vs. obese; 5.8 + 1.1). 
Insulin Stimulated Insulin Signaling   
Obesity is associated with impaired insulin induced signaling and lipid overload can 
induce similar impairments in insulin-induced signaling in lean, even in primary cell 
culture (Bell et al., 2010).  We questioned if hyperinsulinemia would impair insulin-
induced signaling in primary skeletal muscle cells isolated from lean individuals to levels 
observed in obese.  Figure 8 depicts the Akt and AS160 response to acute stimulation 
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in lean and obese following chronic incubation with low or high physiological levels of 
insulin.  There was a trend (p=0.11) for lower insulin-induced Akt phosphorylation in OB 
compared to LN regardless of insulin incubation conditions consistent with cells from 
obese being insulin resistant compared to leans (Fig. 8A).  There was no effect of 
hyperinsulinemia on insulin-induced Akt phosphorylation.  However, hyperinsulinemia 
significantly increased insulin-induced AS160 phosphorylation in LN, but not OB (Fig. 
8B).  Thus, in human primary skeletal muscle cells from lean individuals 
hyperinsulinemia increases insulin signaling and this response is attenuated in obese.  
Fatty Acid Oxidation (FAO)   
Muscle (in vivo or primary skeletal muscle cell culture) from obese individuals 
demonstrates impaired FAO (Bell et al., 2010; Guesbeck et al., 2001).  Figure 9 shows 
FAO from LN and OB following chronic hyperinsulinemia.  Complete FAO (Fig. 9A) was 
lower and ASM/CO2 (Fig. 9C) was higher in OB compared to LN.  There was no effect 
of hyperinsulinemia on complete FAO, total FAO or ASM/CO2.  As the ASM/CO2 ratio is 
often referred to as a measurement of FAO efficiency, these results offer further 
evidence that severely obese individuals exhibit less efficient FAO compared to lean 
individuals (Bell et al., 2010; Consitt et al., 2010; Kim et al., 2000). 
Citrate Synthase Activity (CSA) and COXIV   
As reduced mitochondrial content has been implicated in obesity related insulin 
resistance and to identify a potential mechanism for reduced FAO in cells from obese, 
we measured COXIV and CSA as indexes of mitochondrial content (Fig. 10).  There 
was no difference in CSA (Fig. 10A) or COXIV content (Fig. 10B) between the LN and 
OB.  There was no effect of hyperinsulinemia on either CSA or COXIV in the LN or OB.  
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Linear regression reveals a significant correlation between mitochondrial content 
measured by CSA and COXIV (Fig. 10C) supporting the use of these measures for 
mitochondrial content.  These results suggest that differences in FAO between LN and 
OB do not appear to be due to differences in mitochondrial content in the current 
experiments.      
DISCUSSION 
 Our initial hypothesis was that exposure to chronic hyperinsulinemia would down-
regulate insulin signaling in both lean and obese primary human cell cultures.  While 
there was no decrease in insulin signaling in either group, the LN group responded to 
the acute insulin stimulation by increasing AS160 phosphorylation while the OB group 
did not exhibit a similar response. These results suggest that the LN group retains 
flexibility allowing up-regulation of insulin signaling in response to hyperinsulinemia 
while the OB group does not experience a similar response.  
 The current report is in conflict with previous reports that hyperinsulinemia can 
induce insulin resistance in vivo (Del Prato et al., 1994; Iozzo et al., 2001; Rizza et al., 
1985) and in myotubes (Ciaraldi et al., 1995).  One possible explanation for these 
results is that in the current study a physiological concentration of hyperinsulinemia 
(approximately 5,000 pM) was utilized whereas prior reports used pharmacologic 
concentrations (approximately 30 µM) (Ciaraldi et al., 1995).  Also, Rizza et al. reported 
that glucose utilization decreases following a 40h continuous exposure to 
hyperinsulinemia thus suggesting that hyperinsulinemia induces whole body insulin 
resistance (Rizza et al., 1985).  However, it is possible this hyperinsulinemia-induced 
insulin resistance is due to a specific reduction in glycogen synthesis and is not a result 
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of the down regulation the IRS signaling cascade that is responsible for insulin-induced 
GLUT4 translocation to t-tubule sarcolemma.  It has been documented that 48-72h of 
euglycemic hyperinsulinemia decreases whole body glucose uptake and this is 
predominantly due to a reduction in glycogen formation (Del Prato et al., 1994).  Follow 
up studies elucidated that 24h of physiological hyperinsulinemia induces insulin 
resistance by decreasing insulin induced glycogen synthase in skeletal muscle, yet 
GLUT4 protein content was unchanged (Iozzo et al., 2001).  Therefore, it is possible 
that physiological hyperinsulinemia induces insulin resistance by decreasing whole body 
glucose utilization but this may be independent of the insulin mediated insulin signaling 
cascade. 
 In support of this divergent response to physiological hyperinsulinemia, AS160 
phosphorylation in skeletal muscle, when exposed to physiological hyperinsulinemia, is 
increased in normal control subjects while T2DM subjects exhibit reduced AS160 
phosphorylation compared to lean (Karlsson et al., 2005).  Also, it is possible that 
AS160 remained phosphorylated following the 5 hour insulin starvation, similar to 
phosphorylation observed post exercise 2.5 hours (Sriwijitkamol et al., 2007) and 14 
hours following exercise (Frosig et al., 2007).   While AS160 is rapidly dephosphorylated 
following the removal of rat skeletal muscle from insulin, the long term effects of insulin 
exposure are not known at the cellular level (Sharma, Arias, & Cartee, 2010).   
Additionally, Hoy et. al., (Hoy et al., 2009) demonstrated that physiological levels (~300 
mU/l) of insulin added during a lipid infusion in rats resulted in an increase in skeletal 
muscle insulin resistance but that increase was independent of the insulin signaling 
pathway as no changes in Akt or AS160 were observed.  Similarly, it has been reported 
  66 
in rats that glucose infusion can result in skeletal muscle insulin resistance without 
dysregulation of the insulin signaling pathway due to decreases in glucose uptake and 
glycogen synthesis, but no changes in Akt or AS160 phosphorylation (Hoy et al., 2007).  
These data suggest that factors other than differences in insulin signaling in the 
metabolism of lipids or glucose could contribute to hyperinsulinemia-induced insulin 
resistance.  
 There was a disconnect in the insulin signaling pathway from Akt to AS160 
where the LN group did not experience a significant increase in Akt phosphorylation in 
response to insulin induced insulin stimulation but did in AS160 following 
hyperinsulinemia incubation.  It is possible there are alternate substrates other than Akt 
that phosphorylate AS160 which is consistent with a report from our lab that exhibited a 
similar disconnect between Akt and AS160 in response to lipid induced insulin 
resistance (Bikman et al., 2010).   Another possibility for the disconnect between Akt 
and AS160 is that with a 15-minute acute supraphysiological stimulation we have 
missed maximal pAktThr308 signaling in the myotubes but have reported maximal 
pAS160Thr642 signaling.  Five, 10 and 15 minutes have been reported to induce maximal 
pAktThr308 stimulation in mouse skeletal muscle (Witczak et al., 2010) but the exact time 
required for similar stimulation in primary human skeletal muscle cell culture is not 
known, indicating perhaps pAktThr308 stimulation was already decreasing while 
downstream pAS160Thr642 was maximally phosphorylated.  Also in the report by Bikman 
et. al., the myotubes from lean were able to up-regulate AS160 phosphorylation in 
response to a 16 hour lipid exposure while myotubes form obese did not (Bikman et al., 
2010).  Similar to those findings, in the current study, the OB group experienced a 
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decreased ability to respond to the hyperinsulinemic challenge compared to the LN 
group.  These data suggest the muscle from obese, insulin resistant exhibit an impaired 
response in insulin-induced insulin signaling compared to muscle from lean, insulin 
sensitive.    
 Additionally, we observed that complete FAO was decreased in the OB group 
independent of insulin concentration.  Reduced FAO in cells from obese is consistent 
with studies that have reported depressed FAO in skeletal muscle homogenates (Kim et 
al., 2000), intact muscle strips (Hulver et al., 2003), primary human skeletal muscle cell 
culture (Bell et al., 2010), during lipid infusions (Thyfault et al., 2004)  and via indirect 
calorimetry (Guesbeck et al., 2001).  Also, the OB group exhibit increased 
incomplete:complete FAO indicating the muscle from obese have higher levels of 
incomplete oxidation and thus less efficient fatty acid oxidation.  This was observed 
during both normal and hyperinsulinemia suggesting that chronic hyperinsulinemia does 
not affect fatty acid oxidation, rather that muscle from obese experiences a persistent 
decrease in oxidation compared to muscle from lean. 
 Reduced mitochondrial content has been implicated as a likely cause of reduced 
FAO in obesity and is associated with insulin resistance (Consitt et al., 2010; Morino et 
al., 2005).  Mitochondrial content was determined in order to account for potential 
differences in FAO and there were no differences in either CSA or COXIV protein 
between the LN and OB groups, which suggests that the decrease in complete FAO is 
not due to decreased mitochondrial content in the OB group.  Also, we found no 
differences in mitochondrial content between groups at either insulin concentration 
indicating that hyperinsulinemia does not affect mitochondrial content.  These results 
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suggest muscle mitochondrial content may not be different between lean and obese and 
that reduced fatty acid oxidation may be due to mitochondrial dysfunction (Kelley et al., 
2002; Koves et al., 2008). 
 In summary, it appears that when challenged with hyperinsuliemia, muscle from 
obese exhibit decreased flexibility to hyperinsulinemia compared to muscle from lean in 
which hyperinsulinemia increases AS160 phosphorylation.  This appears to be 
independent of mitochondrial content as both citrate synthase and COXIV were 
unchanged between the LN and OB groups for both insulin conditions.  Additionally, 
though complete fatty acid oxidation was decreased and the ratio of 
incomplete:complete FAO was increased in the OB group this was independent of 
insulin and appears to be a defect inherent in the OB group.  These results suggest that 
hyperinsulinemia-induced insulin resistance in skeletal muscle is not due to decreased 
insulin signaling but rather to other pathways involved in glucose transport and disposal.   
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Figure 8.  The effects of 4d of low (80 pM) or high (5000 pM) insulin on insulin-
stimulated insulin signaling in pooled lean (open bars) and obese (filled bars) myotubes 
from human participants.  Myotubes were probed for p-AKT (A) and p-AS160 (B), AU 
(Arbitrary Units). * Significant interaction with post-hoc testing indicating significantly 
different from all other time points (p<0.05).  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Figure 9.  The effects of 4d of low (80 pM) or high (5000 pM) insulin on fatty acid 
oxidation in pooled lean (open bars) and obese (filled bars) myotubes from human 
participants.  Complete FAO was measured from 14C-labeled incorporation into CO2 (A).  
Total FAO (B) was calculated as the sum of 14C-labeled incorporation into CO2 and 14C-
labeled incorporation into acid-soluble metabolites, which is a measurement of 
incomplete FAO.  FAO efficiency was calculated as the ratio of ASM to complete FAO, 
represented as ASM/CO2 (C). * Significant main effect of BMI (p<0.05) 
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Figure 10.  The effects of 4d of low (80 pM) or high (5000 pM) insulin on mitochondrial 
content in pooled lean (open bars) and obese (filled bars) myotubes from human 
participants.  Myotubes were measure for citrate synthase activity (A) and probed for 
COXIV (B), AU (Arbitrary Units).  Additionally, a correlation was performed between 
COXIV and citrate synthase activity (C). 
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CHAPTER 5:  Integrated Discussion 
 The development of T2DM is characterized by insulin resistance, chronic 
hyperinsulinemia and, over time, pancreatic β cell failure (DeFronzo, 2004).  
Specifically, skeletal muscle in T2DM exhibits insulin resistance, decreased substrate 
oxidation and mitochondrial dysfunction (Kelley et al., 2002; Ritov et al., 2005).  Yet, the 
exact mechanism(s) responsible for the development of T2DM are not clearly 
elucidated.  While T2DM becomes progressively difficult to manage pharmacologically, 
RYGB has proven to ameliorate T2DM in approximately 80% of T2DM patients and this 
reversal is durable, with patients as long as 14 years post-RYGB reporting successful 
continued remission of T2DM (Flickinger et al., 1984).  These improvements are likely a 
result of improved insulin sensitivity and insulin secretion following RYGB but exact 
mechanisms for the reversal of T2DM remain unknown.   
 In Chapter 2 (Study One), we observed a significant decrease in fasting insulin in 
T2DM patients to levels similar to lean controls by one week following RYGB even 
though fasting glucose, while reduced, remained elevated.  This finding indicates that 
RYGB alters insulin regulation such that fasting insulin is dissociated from glucose and 
suggests that post-RYGB fasting insulin may be regulated by mechanisms other than 
glucose.  Future work in this area is needed to determine the exact mechanism by 
which fasting insulin is restored to normal following RYGB seemingly independent of 
fasting glucose. 
 Though there was great improvement of T2DM following RYGB in Chapter 2, our 
results were consistent with the literature in that approximately 20% of patients do not 
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exhibit T2DM remission following RYGB.  Of the patients with T2DM, three patients 
experienced complete diabetes reversal (FPG < 100 mg/dL), three had impaired blood 
glucose (FPG 100-124 mg/dL), indicating some improvement in their T2DM and two 
patients that did not respond to RYGB and remained diabetic (FPG > 125 mg/dL) 
following RYGB.  Therefore, approximately 25% of patients did not experience 
remission of diabetes following RYGB.  There has been no specific mechanism defined 
that can explain unsuccessful resolution of T2DM following RYGB.  Previously, several 
factors have been associated with T2DM resolution following RYGB including disease 
severity (as indicated by the use multiple pharmacological therapies and/or exogenous 
insulin), length of the disease, inadequate control of blood glucose (as indicated by a 
high HbA1c), low BMI and the presence of hypertension (Hall et al., 2010; Hayes et al., 
2011).  However, it was not known mechanistically what may contribute to T2DM 
resolution.  We questioned if insulin sensitivity and insulin secretion pre-RYGB are 
predictive of post-RYGB diabetes remission.  It was the overall goal of Study Two 
(Chapter 3) to determine potential mechanisms responsible for the amelioration of 
T2DM following RYGB. 
 In Chapter 3 we reported that pre-RYGB insulin sensitivity appears to be a 
predictor in the resolution of T2DM post-RYGB.  Insulin sensitivity was correlated with 
FPG 3-months post-RYGB and patients with the greatest insulin sensitivity prior to 
RYGB experienced greater diabetes remission 3-months post-RYGB (defined as FPG 
>100mg/dl and no diabetic medication) compared to those patients that had low insulin 
sensitivity prior to RYGB.  Also, duration of T2DM prior to surgery was negatively 
correlated with T2DM remission following RYGB, consistent with previous reports.  
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There was no association between pre-RYGB insulin secretion and T2DM reversal 
following RYGB suggesting that differences in insulin sensitivity between patients, but 
not insulin secretion are important for T2DM remission following RYGB.    
 Together, with the results from Chapter 2 indicating that the return of insulin to 
normal is an early and potentially important in RYGB-induced T2DM resolution and 
Chapter 3 that pre-RYGB insulin sensitivity is associated with remission of T2DM 
success following RYGB, we questioned if hyperinsulinemia could produce insulin 
resistance.  Specifically, it was hypothesized that hyperinsulinemia would lower insulin-
induced insulin signaling (Akt and AS160) in myotubes from both lean insulin sensitive  
(LN) and obese insulin resistant (OB) individuals.  As insulin resistance is also 
associated with depressed fatty acid oxidation and mitochondrial dysfunction, we 
hypothesized that chronic hyperinsulinemia would lower fatty acid oxidation and 
mitochondrial content. 
 In Chapter 4, it was reported that while hyperinsulinemia did not induce insulin 
resistance in either LN or OB, LN and OB experienced divergent insulin signaling 
responses.  In response to chronic hyperinsulinemia, LN responded by increasing 
AS160 phosphorylation whereas OB did no suggesting OB have a blunted response to 
chronic hyperinsulinemia.  Given that hyperinsulinemia is known to induce insulin 
resistance, these results suggest that insulin resistance may not occur through 
decreased insulin signaling and implicates other mechanisms responsible for 
hyperinsulinemia-induced insulin resistance. 
 Also noted in Chapter 4, there were no differences in mitochondrial content 
between LN and OB for either insulin concentration.  Even though there were no 
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observed differences in mitochondrial content, incomplete fatty acid oxidation was 
increased and complete fatty acid oxidation was decreased in the OB compared to LN.  
This finding suggests that in the current study mitochondrial content may not be 
different between lean and obese, but that obese may not be as efficient in oxidizing 
fatty acids compared to leans.   
 In summary, it appears that RYGB may contribute to the amelioration of T2DM 
by reducing hyperinsulinemia and perhaps removing a currently unknown stimulus for 
insulin production.  Further research is necessary to elucidate the exact mechanism by 
which RYGB acts to reverse hyperinsulinemia in T2DM patients within one-week of 
RYGB.  This finding, along with the novel discovery that pre-RYGB insulin sensitivity is 
predictive of remission of T2DM post-RYGB have significant implications for clinical 
management of T2DM that may need to focus on the importance of maintaining insulin 
sensitivity.  Finally, the finding that there is a divergent response in AS160 
phosphorylation in response to hyperinsulinemia in cells from lean insulin sensitive and 
obese insulin resistant individuals suggests that hyperinsulinemia-induced insulin 
resistance occurs through pathways other than those through AS160 and warrants 
further exploration.            
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